{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.36","value":"2.1"},{"groupId":"OG001","spread":"37.27","value":"-0.3"},{"groupId":"OG002","spread":"25.65","value":"4.5"}]}],"title":"Cycle 4 - approximately Month 4 (n=110,117,119)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.32","value":"3.8"},{"groupId":"OG001","spread":"37.94","value":"2.6"},{"groupId":"OG002","spread":"27.78","value":"5.2"}]}],"title":"Cycle 7 - approximately Month 7 (n=88,104,108)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.32","value":"7.6"},{"groupId":"OG001","spread":"43.69","value":"-4.0"},{"groupId":"OG002","spread":"26.72","value":"3.9"}]}],"title":"Cycle 10 - approximately Month 10 (n=79,83,94)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.01","value":"1.0"},{"groupId":"OG001","spread":"44.23","value":"-0.5"},{"groupId":"OG002","spread":"32.51","value":"5.1"}]}],"title":"Cycle 13 - approximately Month 13 (n=68,72,79)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.58","value":"3.4"},{"groupId":"OG001","spread":"41.25","value":"6.4"},{"groupId":"OG002","spread":"28.08","value":"2.7"}]}],"title":"Cycle 16 - approximately Month 16 (n=59,52,61)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"153"},{"groupId":"OG002","value":"154"}],"units":"Participants"}],"description":"Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the body image scale, higher scores = better body image.","dispersionType":"Standard Deviation","groups":[{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG000","title":"MPR+R"},{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG001","title":"MPR+p"},{"description":"Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG002","title":"MPp+p"}],"paramType":"MEAN","populationDescription":"Intent to treat population","reportingStatus":"POSTED","timeFrame":"Baseline (Day 0), Months 4, 7, 10, 13, 16","title":"Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Body Image Scale","type":"SECONDARY","unitOfMeasure":"units on a scale"}